Baxter Stock Plummets 15% After Mixed Q3 Earnings – What Investors Should Know
Mixed Third-Quarter Financial Results Baxter’s Q3 showed a mixed picture. Revenue from continuing operations rose about 5% year-over-year to $2.84 billion, helped by strong performance in its Pharmaceuticals and Healthcare Systems units baxter.com baxter.com. However, sales fell short of the street’s ~$2.88 billion estimate reuters.com. On profit, Baxter earned an adjusted $0.69 per share, well above the ~$0.60 expected reuters.com chartmill.com. (GAAP results showed a small net loss as some one-time costs were excluded from the adjusted figure baxter.com.) Despite the earnings beat, investors focused on the revenue miss. The stock tumbled ~15% in early trading on Oct. 30, 2025 reuters.com chartmill.com.